Retatrutide, a new dual activator of the GLP-1 target and glucose-dependent released polypeptide (GIP) receptor , is showing promising outcomes in preliminary clinical assessments . Ongoing inquiry indicates that retatrutide may offer considerable advantages for patients with diabetes , particularly regarding weight reduction and blood sugar regula